25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions.

Truong, Thach-Giao; Kennedy, Lucy Boyce; Patel, Sapna P

Truong, Thach-Giao; Kennedy, Lucy Boyce; Patel, Sapna P.

Affiliation

Truong TG; Kaiser Permanente Northern California, 975 Sereno Drive, Vallejo, CA, 94589, USA.
Kennedy LB; The Cleveland Clinic Foundation, 9500 Euclid Ave CA-60, Cleveland, OH, 44195, USA.
Patel SP; The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0430, Houston, TX, 77030, USA. sppatel@mdanderson.org.

Curr Oncol Rep ; 24(4): 533-542, 2022 04.

Article in En | MEDLINE | ID: mdl-35192117

Subject(s)

Melanoma; Skin Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Humans; Ipilimumab/therapeutic use; Melanoma/drug therapy; Proto-Oncogene Proteins B-raf; Skin Neoplasms/therapy

Key words

AJCC; Adjuvant; Adverse events; BRAF; Biomarkers; Checkpoint; Dabrafenib; Immunotherapy; Interferon; Ipilimumab; Lymph node; Melanoma; Nivolumab; Overall survival; PD-L1; Pembrolizumab; Recurrence-free survival; Resected; Targeted therapy; Toxicity; Trametinib

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Limits: Humans Language: En Journal: Curr Oncol Rep Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google